Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi


  • Hibah Almasmoum
  • Rachel Doidge
  • Gerlof Sebastiaan WinklerEmail author
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_272


Historical Background

The human BTG/Tob proteins form a small family of six proteins, which share a conserved N-terminal domain and antiproliferative activity (Matsuda et al. 2001; Tirone 2001; Winkler 2010). BTG2 was discovered first by two laboratories: as the immediate/early response gene PC3 in rat PC12 cells stimulated with nerve growth factor (NGF) and as TIS21 in mouse 3T3 fibroblasts in response to treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA). The discovery of BTG1 (B-cell translocation gene 1) as a gene involved in a chromosomal translocation associated with chronic lymphocytic leukemia suggested the presence of a new family of antiproliferative genes. These findings were extended by the discovery of TOB1, which was found as an interacting protein of the ErbB2 tyrosine-kinase receptor (HER2). The remaining three members BTG3 (ANA),...

This is a preview of subscription content, log in to check access.


  1. Ajima R, Akiyama T, Usui M, Yoneda M, Yoshida Y, Nakamura T, et al. Osteoporotic bone formation in mice lacking tob2: involvement of Tob2 in RANK ligand expression and osteoclasts differentiation. FEBS Lett. 2008;582:1313–8.  https://doi.org/10.1016/j.febslet.2008.03.012, S0014-5793(08)00241-X [pii]CrossRefPubMedGoogle Scholar
  2. Boiko AD, Porteous S, Razorenova OV, Krivokrysenko VI, Williams BR, Gudkov AV. A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. Genes Dev. 2006;20:236–52.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Ezzeddine N, Chang TC, Zhu W, Yamashita A, Chen CY, Zhong Z, et al. Human TOB, an antiproliferative transcription factor, is a poly(A)-binding protein-dependent positive regulator of cytoplasmic mRNA deadenylation. Mol Cell Biol. 2007;27:7791–801.PubMedPubMedCentralCrossRefGoogle Scholar
  4. Funakoshi Y, Doi Y, Hosoda N, Uchida N, Osawa M, Shimada I, et al. Mechanism of mRNA deadenylation: evidence for a molecular interplay between translation termination factor eRF3 and mRNA deadenylases. Genes Dev. 2007;21:3135–48.PubMedPubMedCentralCrossRefGoogle Scholar
  5. Horiuchi M, Takeuchi K, Noda N, Muroya N, Suzuki T, Nakamura T, et al. Structural basis for the antiproliferative activity of the Tob-hCaf1 complex. J Biol Chem. 2009;284:13244–55.PubMedPubMedCentralCrossRefGoogle Scholar
  6. Hosoda N, Funakoshi Y, Hirasawa M, Yamagishi R, Asano Y, Miyagawa R, et al. Anti-proliferative protein Tob negatively regulates CPEB3 target by recruiting Caf1 deadenylase. EMBO J. 2011;30:1311–23.  https://doi.org/10.1038/emboj.2011.37, emboj201137 [pii]CrossRefPubMedPubMedCentralGoogle Scholar
  7. Matsuda S, Rouault J, Magaud J, Berthet C. In search of a function for the TIS21/PC3/BTG1/TOB family. FEBS Lett. 2001;497:67–72.CrossRefPubMedGoogle Scholar
  8. Mauxion F, Chen CY, Seraphin B, Shyu AB. BTG/TOB factors impact deadenylases. Trends Biochem Sci. 2009;34:640–7.  https://doi.org/10.1016/j.tibs.2009.07.008, S0968-0004(09)00170-4 [pii]CrossRefPubMedPubMedCentralGoogle Scholar
  9. Miyai K, Yoneda M, Hasegawa U, Toita S, Izu Y, Hemmi H, et al. ANA deficiency enhances bone morphogenetic protein-induced ectopic bone formation via transcriptional events. J Biol Chem. 2009;284:10593–600.PubMedPubMedCentralCrossRefGoogle Scholar
  10. Ou YH, Chung PH, Hsu FF, Sun TP, Chang WY, Shieh SY. The candidate tumor suppressor BTG3 is a transcriptional target of p53 that inhibits E2F1. EMBO J. 2007;26:3968–80.PubMedPubMedCentralCrossRefGoogle Scholar
  11. Park S, Lee YJ, Lee HJ, Seki T, Hong KH, Park J, et al. B-cell translocation gene 2 (Btg2) regulates vertebral patterning by modulating bone morphogenetic protein/smad signaling. Mol Cell Biol. 2004;24:10256–62.PubMedPubMedCentralCrossRefGoogle Scholar
  12. Rouault JP, Falette N, Guehenneux F, Guillot C, Rimokh R, Wang Q, et al. Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet. 1996;14:482–6.CrossRefPubMedGoogle Scholar
  13. Stupfler B, Birck C, Seraphin B, Mauxion F. BTG2 bridges PABPC1 RNA-binding domains and CAF1 deadenylase to control cell proliferation. Nat Commun. 2016;7:10811.  https://doi.org/10.1038/ncomms10811.CrossRefPubMedPubMedCentralGoogle Scholar
  14. Suzuki T, J KT, Ajima R, Nakamura T, Yoshida Y, Yamamoto T. Phosphorylation of three regulatory serines of Tob by Erk1 and Erk2 is required for Ras-mediated cell proliferation and transformation. Genes Dev. 2002;16:1356–70.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Tirone F. The gene PC3(TIS21/BTG2), prototype member of the PC3/BTG/TOB family: regulator in control of cell growth, differentiation, and DNA repair? J Cell Physiol. 2001;187:155–65.CrossRefPubMedGoogle Scholar
  16. Usui M, Yoshida Y, Tsuji K, Oikawa K, Miyazono K, Ishikawa I, et al. Tob deficiency superenhances osteoblastic activity after ovariectomy to block estrogen deficiency-induced osteoporosis. Proc Natl Acad Sci U S A 2004;101:6653–6658.  https://doi.org/10.1073/pnas.0303093101, 0303093101 [pii].CrossRefGoogle Scholar
  17. Washio-Oikawa K, Nakamura T, Usui M, Yoneda M, Ezura Y, Ishikawa I, et al. Cnot7-null mice exhibit high bone mass phenotype and modulation of BMP actions. J Bone Miner Res. 2007;22:1217–23.PubMedPubMedCentralCrossRefGoogle Scholar
  18. Winkler GS. The mammalian anti-proliferative BTG/Tob protein family. J Cell Physiol. 2010;222:66–72.  https://doi.org/10.1002/jcp.21919.CrossRefPubMedCentralPubMedGoogle Scholar
  19. Yoshida Y, Nakamura T, Komoda M, Satoh H, Suzuki T, Tsuzuku JK, et al. Mice lacking a transcriptional corepressor Tob are predisposed to cancer. Genes Dev. 2003;17:1201–6.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Hibah Almasmoum
    • 1
    • 2
  • Rachel Doidge
    • 1
  • Gerlof Sebastiaan Winkler
    • 1
    Email author
  1. 1.School of PharmacyUniversity of NottinghamNottinghamUK
  2. 2.School of Medicine and School of PharmacyUniversity of NottinghamNottinghamUK